Example of ACS Medicinal Chemistry Letters format
Recent searches

Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format Example of ACS Medicinal Chemistry Letters format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

ACS Medicinal Chemistry Letters — Template for authors

Categories Rank Trend in last 3 yrs
Organic Chemistry #44 of 185 down down by 18 ranks
Drug Discovery #40 of 145 down down by 15 ranks
Biochemistry #137 of 415 down down by 45 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 1053 Published Papers | 6099 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 15/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Elsevier

Quality:  
Good
CiteRatio: 4.3
SJR: 0.541
SNIP: 0.594
open access Open Access

Elsevier

Quality:  
Good
CiteRatio: 5.4
SJR: 0.803
SNIP: 1.408
open access Open Access

Springer

Quality:  
High
CiteRatio: 4.3
SJR: 0.633
SNIP: 1.433

Royal Society of Chemistry

Quality:  
High
CiteRatio: 6.0
SJR: 0.923
SNIP: 0.776

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

3.975

6% from 2018

Impact factor for ACS Medicinal Chemistry Letters from 2016 - 2019
Year Value
2019 3.975
2018 3.737
2017 3.794
2016 3.746
graph view Graph view
table view Table view

5.8

3% from 2019

CiteRatio for ACS Medicinal Chemistry Letters from 2016 - 2020
Year Value
2020 5.8
2019 6.0
2018 6.3
2017 6.4
2016 6.3
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 6% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has decreased by 3% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.065

8% from 2019

SJR for ACS Medicinal Chemistry Letters from 2016 - 2020
Year Value
2020 1.065
2019 1.158
2018 1.202
2017 1.388
2016 1.412
graph view Graph view
table view Table view

1.064

2% from 2019

SNIP for ACS Medicinal Chemistry Letters from 2016 - 2020
Year Value
2020 1.064
2019 1.041
2018 0.91
2017 0.991
2016 1.081
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has decreased by 8% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 2% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

ACS Medicinal Chemistry Letters

Guideline source: View

Potential, possible, or probable predatory scholarly open-access publishers.

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

American Chemical Society

ACS Medicinal Chemistry Letters

ACS Medicinal Chemistry Letters publishes brief communications on experimental or theoretical results of exceptional timeliness in all aspects of medicinal chemistry (pure and applied) and its extension into pharmacology. The journal publishes studies that range from compound ...... Read More

Drug Discovery

Organic Chemistry

Biochemistry

Pharmacology, Toxicology and Pharmaceutics

i
Last updated on
15 Jul 2020
i
ISSN
1948-5875
i
Impact Factor
High - 1.072
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
White faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
ACS Custom Citation (achemso)
i
Citation Type
Numbered (Superscripted)
25
i
Bibliography Example
Beenakker, C. W. J. Specular Andreev Reflection in Graphene. Phys. Rev. Lett. 2006, 97, 067007.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1021/ML3003346
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.

Abstract:

The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a critical role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer. As part of a drug discovery program targeting EZH2, we have identified highly potent, selective, SAM-competitive, and cell-active EZH2 inhibit... The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a critical role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer. As part of a drug discovery program targeting EZH2, we have identified highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitors, including GSK926 (3) and GSK343 (6). These compounds are small molecule chemical tools that would be useful to further explore the biology of EZH2. read more read less

Topics:

Histone methyltransferase (65%)65% related to the paper, PRC2 (59%)59% related to the paper, EZH2 (57%)57% related to the paper, Histone (54%)54% related to the paper, Methyltransferase (53%)53% related to the paper
View PDF
355 Citations
open accessOpen access Journal Article DOI: 10.1021/ML900028R
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Abstract:

Phosphoinositide 3-kinase α (PI3Kα) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers. The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed ... Phosphoinositide 3-kinase α (PI3Kα) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers. The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition. 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models. Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer. read more read less

Topics:

RPTOR (62%)62% related to the paper, PI3K/AKT/mTOR pathway (61%)61% related to the paper, Cell growth (52%)52% related to the paper, Protein kinase A (50%)50% related to the paper
331 Citations
open accessOpen access Journal Article DOI: 10.1021/ML1000307
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

Abstract:

The blockade of aberrant hedgehog (Hh) signaling has shown promise for therapeutic intervention in cancer. A cell-based phenotypic high-throughput screen was performed, and the lead structure (1) was identified as an inhibitor of the Hh pathway via antagonism of the Smoothened receptor (Smo). Structure−activity relationship s... The blockade of aberrant hedgehog (Hh) signaling has shown promise for therapeutic intervention in cancer. A cell-based phenotypic high-throughput screen was performed, and the lead structure (1) was identified as an inhibitor of the Hh pathway via antagonism of the Smoothened receptor (Smo). Structure−activity relationship studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4′-(trifluoromethoxy)biphenyl-3-carboxamide (5m, NVP-LDE225), which is currently in clinical development. read more read less

Topics:

Smoothened (67%)67% related to the paper, Smoothened Receptor (64%)64% related to the paper, Hedgehog signaling pathway (57%)57% related to the paper
View PDF
298 Citations
open accessOpen access Journal Article DOI: 10.1021/ML4000657
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.

Abstract:

The p53 tumor suppressor is a potent transcription factor that plays a key role in the regulation of cellular responses to stress It is controlled by its negative regulator MDM2, which binds directly to p53 and inhibits its transcriptional activity MDM2 also targets p53 for degradation by the proteasome Many tumors produce hi... The p53 tumor suppressor is a potent transcription factor that plays a key role in the regulation of cellular responses to stress It is controlled by its negative regulator MDM2, which binds directly to p53 and inhibits its transcriptional activity MDM2 also targets p53 for degradation by the proteasome Many tumors produce high levels of MDM2, thereby impairing p53 function Restoration of p53 activity by inhibiting the p53-MDM2 interaction may represent a novel approach to cancer treatment RG7112 (2g) is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2 In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts read more read less

Topics:

Mdm2 (55%)55% related to the paper, Transcription factor (54%)54% related to the paper, Cancer cell (54%)54% related to the paper, Proteasome (53%)53% related to the paper, Cell cycle checkpoint (50%)50% related to the paper
View PDF
295 Citations
open accessOpen access Journal Article DOI: 10.1021/ACSMEDCHEMLETT.7B00421
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

Abstract:

Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated 2-HG levels are implicated in epigenetic alterations... Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation. IDH1 mutations have been described in an array of hematologic malignancies and solid tumors. Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo. Preliminary data from phase 1 clinical trials enrolling patients with cancers harboring an IDH1 mutation indicate that AG-120 has an acceptable safety profile and clinical activity. read more read less

Topics:

Differentiation therapy (54%)54% related to the paper, Mutant (54%)54% related to the paper, Isocitrate dehydrogenase (53%)53% related to the paper, IDH1 (53%)53% related to the paper, Point mutation (52%)52% related to the paper
View PDF
265 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for ACS Medicinal Chemistry Letters.

It automatically formats your research paper to American Chemical Society formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

ACS Medicinal Chemistry Letters format uses ACS Custom Citation (achemso) citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write ACS Medicinal Chemistry Letters in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the ACS Medicinal Chemistry Letters guidelines and auto format it.

2. Do you follow the ACS Medicinal Chemistry Letters guidelines?

Yes, the template is compliant with the ACS Medicinal Chemistry Letters guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in ACS Medicinal Chemistry Letters?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the ACS Medicinal Chemistry Letters citation style.

4. Can I use the ACS Medicinal Chemistry Letters templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for ACS Medicinal Chemistry Letters.

5. Can I use a manuscript in ACS Medicinal Chemistry Letters that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper ACS Medicinal Chemistry Letters that you can download at the end.

6. How long does it usually take you to format my papers in ACS Medicinal Chemistry Letters?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in ACS Medicinal Chemistry Letters.

7. Where can I find the template for the ACS Medicinal Chemistry Letters?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per ACS Medicinal Chemistry Letters's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the ACS Medicinal Chemistry Letters's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. ACS Medicinal Chemistry Letters an online tool or is there a desktop version?

SciSpace's ACS Medicinal Chemistry Letters is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like ACS Medicinal Chemistry Letters?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like ACS Medicinal Chemistry Letters?”

11. What is the output that I would get after using ACS Medicinal Chemistry Letters?

After writing your paper autoformatting in ACS Medicinal Chemistry Letters, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is ACS Medicinal Chemistry Letters's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for ACS Medicinal Chemistry Letters?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for ACS Medicinal Chemistry Letters. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In ACS Medicinal Chemistry Letters?

The 5 most common citation types in order of usage for ACS Medicinal Chemistry Letters are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the ACS Medicinal Chemistry Letters?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per ACS Medicinal Chemistry Letters's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download ACS Medicinal Chemistry Letters in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in ACS Medicinal Chemistry Letters Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to ACS Medicinal Chemistry Letters formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template